Samsung Biologics has signed a contract worth 111.2 billion won ($77 million) with an undisclosed U.S. pharmaceutical firm to provide contract manufacturing organization (CMO) services.

South Korean pharmaceutical and biotechnology companies are on edge as U.S. President Donald Trump signals the introduction ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West ...

Marks a significant advancement in offering new treatment options for patients with rare diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and ...

Samsung Biologics, the country’s leading pharmaceutical contract manufacturing organization (CMO), announced Tuesday it has ...

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

Samsung Biologics, Syneos Health, Thermo Fisher Scientific, and WuXi AppTec dominate the market. These companies offer end-to-end solutions, from drug discovery to clinical trials, providing ...

1 Day 001360 -1.40% DJIA -1.63% S&P 500 -1.54% Health Care/Life Sciences 0.43% ...